![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | ![]() Apellis Pharmaceuticals Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds. | ![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ![]() Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ![]() Kadmon Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C. | |
Founding Date | Founding Date 2002 | Founding Date 2009 | Founding Date 2002 | Founding Date 1989 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Waltham, US HQ Kew East, AU München, DE Zug, CH San Francisco, US Watertown, US | Locations Carlsbad, US HQ | Locations New York, US HQ Cambridge, US South Brunswick Township, US Warrendale, US | |
Employees | Employees 3217% decrease | Employees 7028% decrease | Employees 1,32324% increase | Employees 92716% increase | Employees 43 |
Valuation ($) | Valuation ($) 6.6 b | Valuation ($) 3.3 b | Valuation ($) 36.5 b | Valuation ($) 6.3 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) $396.6m (FY, 2023) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $787.6m (FY, 2023) | Revenue (est.) $8.3m (FY, 2020) |
Cost of goods | Cost of goods N/A | Cost of goods $58.5m (FY, 2023) | Cost of goods $268.2m (FY, 2023) | Cost of goods $9.1m (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $338.1m (FY, 2023) | Gross profit $1.6b (FY, 2023) | Gross profit $778.5m (FY, 2023) | Gross profit N/A |
Net income | Net income ($311.9m) (FY, 2022) | Net income ($528.6m) (FY, 2023) | Net income ($440.2m) (FY, 2023) | Net income ($366.3m) (FY, 2023) | Net income ($108.9m) (FY, 2020) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2023) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 13 (FY, 2023) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2023) | Phase III Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 468.9m | Total funding raised $ 88m | Total funding raised $ 1.5b | Total funding raised N/A | Total funding raised $ 21.3m |
Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds.
View companyAlnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyIonis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View companyKadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.
View company